

# Transcatheter Mitral & Tricuspid

## Selected Graphics

**Medtronic**

2020 Institutional Investor & Analyst Day

October 14, 2020



INVESTOR DAY 2020

**Nina Goodheart**

Senior Vice President and President, Structural Heart & Aortic



Large unmet need

20M+

Patients suffer from  
moderate and severe  
Mitral Regurgitation &  
Tricuspid Regurgitation

Medtronic



Rapidly  
growing market

\$3B+


By 2025

⋮

\$800M


TODAY

Medtronic


An anatomical illustration of the human heart, viewed from the front. The mitral valve is highlighted in a light yellow color. A transcatheter valve, the Intrepid, is shown implanted in the mitral valve position. The Intrepid valve has a white, diamond-shaped mesh structure with a central opening. The surrounding heart tissue is shown in shades of red and pink. The background is a light gray gradient.

# Intrepid™ transcatheter **mitral** valve replacement

Medtronic



Medtronic



## Apollo pivotal trial redesign

Evaluate the safety & efficacy of Intrepid™ TMVR system

Approved transcatheter repair or surgical mitral valve intervention may not be optimal treatment

Mitral Regurgitation

**Single arm**

Mitral Annular Calcification

**Single arm**

**Medtronic**

An anatomical illustration of the human heart, focusing on the tricuspid valve. The heart is shown in a semi-transparent view, revealing the internal structures. The tricuspid valve is highlighted in a light yellow color. A transcatheter tricuspid valve replacement device, the Intrepid, is shown implanted in the tricuspid valve. The device consists of a white, mesh-like structure with a central yellow component, and it is supported by a catheter. The text "Intrepid™ transcatheter tricuspid valve replacement" is overlaid on the image in a dark blue font.

# Intrepid™ transcatheter tricuspid valve replacement

Medtronic






## Transcatheter tricuspid therapies market

\$200M

By 2025



Medtronic



Large unmet US need

2M

Patients suffer from moderate and severe Tricuspid Regurgitation

Medtronic



**Tricuspid Early Feasibility  
Study Approval**

**+**

**FDA Breakthrough  
Device Designation**

**Medtronic**



**Announcing mitral  
repair development  
partnership**

**Medtronic**



**THE  
FOUNDRY®**


**Medtronic**




half moon  
medical



Medtronic



Medtronic



**half moon**  
medical


**Potential to fully eliminate mitral regurgitation**

**Maintains physiologic function of native anterior leaflet**

**Preserves options for reintervention**

**Potential to address multiple mitral valve disease etiologies**

**Medtronic**




half moon  
medical


US FDA Approval  
Early Feasibility Study  
In Patients with Severe Symptomatic  
Mitral Regurgitation

Medtronic





## Strong pipeline in transcatheter mitral and tricuspid therapies



### Replacement

Intrepid™ Transcatheter Valve system



### Repair

Half Moon Medical partnership

Medtronic